期刊文献+

补肾破血通络方治疗早期糖尿病肾病疗效观察 被引量:3

Clinical Observation of Bushen Poxue Tongluo Formula in Treating Early Diabetic Nephropathy
下载PDF
导出
摘要 目的 :观察补肾破血通络方治疗早期糖尿病肾病的临床疗效。方法 :依照Mogensen诊断分期标准,选择早期糖尿病肾病患者80例为研究对象。患者采用随机数字表法分为治疗组和对照组各40例,治疗组采用糖尿病基础治疗,加用补肾破血通络方,对照组采用糖尿病基础治疗,加缬沙坦80 mg口服,治疗8周后观察两组治疗前后中医证候积分,24 h尿蛋白定量及综合疗效变化,并进行两组疗效比较。结果:补肾破血通络方可明显改善证候积分,减少尿中微量蛋白,显著改善综合疗效,总有效率治疗组97.5%,对照组62.5%,两组疗效比较差异有统计学意义(P<0.05)。结论:补肾破血通络方能有效治疗早期糖尿病肾病,在减少尿中微量蛋白及减缓肾功能损害方面有一定优势。 Objective:To investigate the curative effect of Bushen Poxue Tongluo formula on early diabetic nephropathy(DN). Methods:DN patients(n=80) were chosen according to Mogensen criterion and divided randomly into treatment group and control group(n=40). The control group was treated with Valsartan besides of basic treatment. Treatment group was treated with Bushen Poxue Tongluo formula besides of the same treatment as the control group. After 8 weeks,observed the curative effect of syndrome integrals,quantitation of urine protein,combining effect and analyzed statistically. Results:Bushen Poxue Tongluo formula decrease syndrome integrals,reduce quantitation of urine protein,improve combining effect. The total effective rate in the treatment group was higher than that in the control group(P〈0.05),with 97.5% in the treatment group and 62.5% in the control group. Conclusion:Bushen Poxue Tongluo formula can effectively treat early DN,reduce quantitation of urine protein,improve kidney function.
出处 《山东中医药大学学报》 2016年第1期40-41,共2页 Journal of Shandong University of Traditional Chinese Medicine
关键词 早期糖尿病肾病 补肾破血通络方 微量蛋白尿 肾功能 疗效观察 early diabetic nephropathy Bushen Poxue Tongluo formula urine protein kidney function effi ciency observation
  • 相关文献

参考文献5

二级参考文献44

共引文献32

同被引文献30

  • 1张勇.辨证治疗糖尿病肾病50例[J].河南中医学院学报,2007,22(3):55-56. 被引量:10
  • 2Liu Z,Fu C,Wang W,et al.Prevalence of chronic complications of type 2 diabetes mellitus in outpatients-a cross-sectional hospital based survey in urban China[J].Health Qual Life Outcomes,2010(8):62.
  • 3Shawn S,Farhad R.New Insights Into Molecular Mechanisms of Diabetic Kidney Disease[J].Am J Kidney Dis,2014,63(202):63-83.
  • 4Quiroga B,Arroyo D,Arriba G.Present and future in the treatment of diabetic kidney disease[J].Journal ofD iabetes Res,2015,2015:801348.
  • 5Ivory SE,Packham DK,Reutens AT,et al.Collaborative Study Group.Residual proteinuria and eG FR predict progression ofrenal impairment within 2 years in type 2 diabetic patients with nephropathy who are receiving optimal treatment with angiotensin receptor blockers[J].Nephrology(Carlton),2013,18(7):516-524.
  • 6Kuhad A,Sachdeva A K,Chopra K.Attenuation of renoinflammatory cascade in experimental model of diabetic nephropathy by sesamol[J].J Agric Food Chem,2009,57(14):6123-6128.
  • 7Vallon V.The proximal tubule in the pathophysiology of the diabetic kidney[J].American Journal of Physiology-Regulatory,Integrative and Comparative Physiology,2011,300(5):1009.
  • 8Tarabra E,Giunti S,Barutta F,et al.Effect of the monocyte chemoattractant protein-1/CC chemokine receptor 2 system on nephrin expression in streptozotocin-treated mice and human cultured podocytes[J].Diabetes,2009,58:2109-2118.
  • 9高彦彬,刘铜华,李平.糖尿病肾病中医防治指南[J].中国中医药现代远程教育,2011,9(4):151-153. 被引量:357
  • 10中华医学会糖尿病学分会.中国2型糖尿病防治指南(2013年版)[J].中国糖尿病杂志,2014,22(8). 被引量:6733

引证文献3

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部